This article is more than 5 years old. Information may no longer be current.

FDA approves Yupelri for adults with COPD

The FDA has approved Yupelri for the maintenance treatment of adult patients with chronic obstructive pulmonary disease, according to a press release.

Yupelri (revefenacin, Thervance Biopharma, Mylan) is a long-acting muscarinic antagonist that helps improve lung function in patients with COPD.

Last year, the once-daily nebulized bronchodilator demonstrated positive results in a phase 3 trial. In 1,055 patients with COPD, revefenacin was well tolerated with no new safety issues reported. It also demonstrated clinically meaningful improvements in moderate-to-sever COPD after 12 weeks compared to placebo in two separate studies.